Takeda delivers another strong quarter

Japan’s largest drugmaker Takeda Pharma (TYO: 4502) today announced financial results for the third quarter of fiscal year 2022 (period ended December 31, 2022).

Takeda noted that revenues for the quarter were 3,071 billion yen ($23.6 billion), a year-on-year increase of 13.9%. Net profit came in at 285.9 billion yen a rise of 18.4%, resulting in earnings per share (EPS) of 184 yen, up 19.6%.

Commenting on the results, Takeda’s chief financial officer Costa Saroukos noted: “Our third-quarter performance demonstrates sustained momentum as our Growth and Launch Products and solid commercial execution again drove strong revenue and core profit growth. We continue to advance our organic pipeline, including notable approvals in the EU and China, and in December announced a significant acquisition that will add a potentially best-in-class TYK2 inhibitor to our late-stage pipeline and enhance our long-term growth strategy. Our robust cash flow and strong financial position enabled us to make substantive progress in deleveraging even as we continued to invest for growth.”